TreeFrog Therapeutics Raises $75M In Series B Financing

15 Sep, 2021

TreeFrog Therapeutics Raises $75M In Series B Financing
Photo by Sinjin Thomas on Unsplash

– TreeFrog Therapeutics, a Bordeaux, France-based biotech startup focused on developing stem cell-derived cell therapies for millions of patients, closed a $75m (€64M) Series B financing round, bringing the total funding to date to $83m (€70m).
– The round was led by Bpifrance Large Venture, part of the French Public Investment Bank, joined by U.S. investment firm Leonard Green & Partners L.P., global pharmaceutical company Bristol Myers Squibb, and European venture capital team XAnge.
– The company intends to use the funds to deploy biomimetic C-StemTM technology for clinical-grade manufacturing, grow and advance to the clinic a comprehensive pipeline of cell therapies, and finance the opening of technological hubs in Boston, MA, and Kobe, Japan.

Biopharma Biotechnology Therapeutics Western Europe
Crunchbase icon

Content report

The following text will be sent to our editors: